Nonclassical congenital adrenal hyperplasia (NCAH) can lead to the production of excess male hormones. It is usually a mild condition and often doesn’t need to be treated. Nonclassical ...

Congenital adrenal hyperplasia (CAH) is a group of genetic conditions that hinders normal hormone levels in your adrenal ...

Cite this: ‘Game Changer’ Approved for Congenital Adrenal Hyperplasia - Medscape - December 17, 2024. Comments Commenting is limited to medical professionals.

BOSTON — Crinecerfont, an investigational oral selective corticotropin-releasing factor type 1 receptor antagonist, benefits both adults and children with congenital adrenal hyperplasia (CAH ...

Congenital adrenal hyperplasia is a condition that causes the adrenal glands to produce too much androgen, the male sex hormone. This may result in early puberty and other symptoms.

Study shows crinecerfont aids patients with congenital adrenal hyperplasia. Crinecerfont results in a greater decrease from baseline in the mean daily glucocorticoid dose among patients with ...

References: Neurocrine Biosciences announces FDA approval of Crenessity™ (crinecerfont), a first-in-class treatment for children and adults with classic congenital adrenal hyperplasia.

BOSTON — Adults with congenital adrenal hyperplasia receiving an oral nonsteroidal treatment saw a marked reduction in daily glucocorticoid dose at 24 weeks with maintenance of androgen control ...

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to ...

Learn about a new drug for classic congenital adrenal hyperplasia (CAH). A top expert explains crinecerfont and its benefits, how it works, and its impact on CAH treatment.

CRF1 receptor antagonists in congenital adrenal hyperplasia: A systematic review and meta-analysis of phase 2 open-label and phase 3 clinical trials, Endocrine and Metabolic Science, 18, (100247 ...